CLDX logo

Celldex Therapeutics (CLDX) Free cash flow

annual FCF:

-$159.70M-$50.59M(-46.36%)
December 31, 2024

Summary

  • As of today (July 4, 2025), CLDX annual free cash flow is -$159.70 million, with the most recent change of -$50.59 million (-46.36%) on December 31, 2024.
  • During the last 3 years, CLDX annual FCF has fallen by -$97.54 million (-156.92%).
  • CLDX annual FCF is now -1040.78% below its all-time high of $16.98 million, reached on December 31, 2008.

Performance

CLDX Free cash flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherCLDXcash flow metrics

quarterly FCF:

-$54.64M-$21.41M(-64.41%)
March 31, 2025

Summary

  • As of today (July 4, 2025), CLDX quarterly free cash flow is -$54.64 million, with the most recent change of -$21.41 million (-64.41%) on March 31, 2025.
  • Over the past year, CLDX quarterly FCF has dropped by -$13.65 million (-33.32%).
  • CLDX quarterly FCF is now -250.09% below its all-time high of $36.40 million, reached on March 31, 2006.

Performance

CLDX quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherCLDXcash flow metrics

TTM FCF:

-$173.35M-$13.65M(-8.55%)
March 31, 2025

Summary

  • As of today (July 4, 2025), CLDX TTM free cash flow is -$173.35 million, with the most recent change of -$13.65 million (-8.55%) on March 31, 2025.
  • Over the past year, CLDX TTM FCF has dropped by -$52.41 million (-43.34%).
  • CLDX TTM FCF is now -598.28% below its all-time high of $34.79 million, reached on March 31, 2006.

Performance

CLDX TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherCLDXcash flow metrics

Free cash flow Formula

FCF = Cash From Operations − CAPEX

CLDX Free cash flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-46.4%-33.3%-43.3%
3 y3 years-156.9%-117.6%-152.6%
5 y5 years-238.7%-342.6%-269.9%

CLDX Free cash flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-156.9%at low-185.3%+2.2%-118.2%at low
5 y5-year-280.6%at low-901.0%+2.2%-313.2%at low
alltimeall time-1040.8%at low-250.1%+2.2%-598.3%at low

CLDX Free cash flow History

DateAnnualQuarterlyTTM
Mar 2025
-
-$54.64M(+64.4%)
-$173.35M(+8.6%)
Dec 2024
-$159.70M(+46.4%)
-$33.23M(-40.5%)
-$159.70M(+0.0%)
Sep 2024
-
-$55.88M(+88.8%)
-$159.66M(+29.9%)
Jun 2024
-
-$29.60M(-27.8%)
-$122.93M(+1.6%)
Mar 2024
-
-$40.98M(+23.4%)
-$120.94M(+10.8%)
Dec 2023
-$109.11M(+3.4%)
-$33.20M(+73.4%)
-$109.11M(+11.4%)
Sep 2023
-
-$19.15M(-30.6%)
-$97.91M(-14.3%)
Jun 2023
-
-$27.61M(-5.3%)
-$114.29M(+4.3%)
Mar 2023
-
-$29.15M(+32.5%)
-$109.61M(+3.8%)
Dec 2022
-$105.56M(+69.8%)
-$22.00M(-38.1%)
-$105.56M(+7.2%)
Sep 2022
-
-$35.54M(+55.1%)
-$98.44M(+23.9%)
Jun 2022
-
-$22.92M(-8.7%)
-$79.46M(+15.8%)
Mar 2022
-
-$25.11M(+68.8%)
-$68.62M(+10.4%)
Dec 2021
-$62.16M(+48.2%)
-$14.88M(-10.1%)
-$62.16M(+17.9%)
Sep 2021
-
-$16.56M(+37.1%)
-$52.74M(+9.4%)
Jun 2021
-
-$12.07M(-35.3%)
-$48.20M(-0.1%)
Mar 2021
-
-$18.65M(+241.7%)
-$48.26M(+15.0%)
Dec 2020
-$41.96M(-11.0%)
-$5.46M(-54.6%)
-$41.96M(-11.9%)
Sep 2020
-
-$12.02M(-0.9%)
-$47.60M(+1.6%)
Jun 2020
-
-$12.13M(-1.7%)
-$46.86M(+1.7%)
Mar 2020
-
-$12.35M(+11.2%)
-$46.07M(-2.3%)
Dec 2019
-$47.15M(-38.0%)
-$11.11M(-1.6%)
-$47.15M(-8.7%)
Sep 2019
-
-$11.28M(-0.5%)
-$51.63M(-5.8%)
Jun 2019
-
-$11.34M(-15.5%)
-$54.80M(-10.4%)
Mar 2019
-
-$13.42M(-13.9%)
-$61.19M(-19.5%)
Dec 2018
-$76.05M(-25.2%)
-$15.59M(+7.9%)
-$76.05M(-5.1%)
Sep 2018
-
-$14.45M(-18.5%)
-$80.17M(-11.3%)
Jun 2018
-
-$17.73M(-37.3%)
-$90.36M(-4.2%)
Mar 2018
-
-$28.28M(+43.5%)
-$94.36M(-7.2%)
Dec 2017
-$101.72M(-12.1%)
-$19.71M(-20.0%)
-$101.72M(-1.2%)
Sep 2017
-
-$24.64M(+13.4%)
-$103.00M(-0.1%)
Jun 2017
-
-$21.73M(-39.0%)
-$103.11M(-11.1%)
Mar 2017
-
-$35.64M(+69.8%)
-$115.98M(+0.2%)
Dec 2016
-$115.79M(+11.6%)
-$20.99M(-15.2%)
-$115.79M(+6.3%)
Sep 2016
-
-$24.76M(-28.4%)
-$108.95M(-3.9%)
Jun 2016
-
-$34.60M(-2.4%)
-$113.34M(+7.9%)
Mar 2016
-
-$35.44M(+150.4%)
-$105.06M(+1.2%)
Dec 2015
-$103.76M(+0.3%)
-$14.15M(-51.5%)
-$103.76M(-7.3%)
Sep 2015
-
-$29.15M(+10.8%)
-$111.99M(+1.7%)
Jun 2015
-
-$26.31M(-23.0%)
-$110.10M(+4.3%)
Mar 2015
-
-$34.15M(+52.6%)
-$105.55M(+2.0%)
Dec 2014
-$103.47M(+43.9%)
-$22.38M(-17.9%)
-$103.47M(+5.2%)
Sep 2014
-
-$27.26M(+25.3%)
-$98.36M(+9.9%)
Jun 2014
-
-$21.75M(-32.2%)
-$89.54M(+3.4%)
Mar 2014
-
-$32.07M(+85.6%)
-$86.60M(+20.5%)
Dec 2013
-$71.89M(+43.5%)
-$17.27M(-6.3%)
-$71.89M(+5.6%)
Sep 2013
-
-$18.44M(-2.0%)
-$68.05M(+12.2%)
Jun 2013
-
-$18.81M(+8.4%)
-$60.63M(+12.6%)
Mar 2013
-
-$17.36M(+29.2%)
-$53.85M(+7.5%)
Dec 2012
-$50.09M(+38.5%)
-$13.44M(+22.0%)
-$50.09M(+8.6%)
Sep 2012
-
-$11.02M(-8.5%)
-$46.13M(+6.5%)
Jun 2012
-
-$12.04M(-11.4%)
-$43.29M(+6.4%)
Mar 2012
-
-$13.60M(+43.5%)
-$40.70M(+12.5%)
Dec 2011
-$36.17M(+11.4%)
-$9.48M(+15.8%)
-$36.17M(+9.1%)
Sep 2011
-
-$8.18M(-13.4%)
-$33.14M(-0.3%)
Jun 2011
-
-$9.45M(+4.2%)
-$33.24M(-2.8%)
Mar 2011
-
-$9.07M(+40.5%)
-$34.21M(+5.4%)
Dec 2010
-$32.47M(+6.8%)
-$6.45M(-22.0%)
-$32.47M(-12.1%)
Sep 2010
-
-$8.28M(-20.6%)
-$36.95M(+7.7%)
Jun 2010
-
-$10.42M(+42.3%)
-$34.29M(+7.1%)
Mar 2010
-
-$7.32M(-33.0%)
-$32.03M(+5.4%)
Dec 2009
-$30.40M(-279.1%)
-$10.93M(+94.5%)
-$30.40M(+67.0%)
Sep 2009
-
-$5.62M(-31.1%)
-$18.20M(-18.9%)
Jun 2009
-
-$8.16M(+43.4%)
-$22.44M(-243.8%)
Mar 2009
-
-$5.69M(-549.1%)
$15.60M(-8.1%)
Dec 2008
$16.98M(-284.5%)
$1.27M(-112.9%)
$16.98M(+37.5%)
Sep 2008
-
-$9.86M(-133.0%)
$12.35M(-59.5%)
Jun 2008
-
$29.89M(-792.0%)
$30.51M(-377.5%)
Mar 2008
-
-$4.32M(+28.5%)
-$10.99M(+19.5%)
Dec 2007
-$9.20M
-$3.36M(-140.5%)
-$9.20M(-79.7%)
Sep 2007
-
$8.30M(-171.5%)
-$45.38M(-24.9%)
DateAnnualQuarterlyTTM
Jun 2007
-
-$11.61M(+359.4%)
-$60.42M(+9.8%)
Mar 2007
-
-$2.53M(-93.6%)
-$55.05M(+241.5%)
Dec 2006
-$16.12M(+167.9%)
-$39.54M(+486.6%)
-$16.12M(-160.0%)
Sep 2006
-
-$6.74M(+8.1%)
$26.85M(-6.8%)
Jun 2006
-
-$6.24M(-117.1%)
$28.80M(-17.2%)
Mar 2006
-
$36.40M(+962.8%)
$34.79M(-678.2%)
Dec 2005
-$6.02M(-41.9%)
$3.43M(-171.5%)
-$6.02M(-47.3%)
Sep 2005
-
-$4.79M(+1859.2%)
-$11.42M(+5.8%)
Jun 2005
-
-$244.60K(-94.4%)
-$10.80M(-12.6%)
Mar 2005
-
-$4.40M(+122.7%)
-$12.35M(+19.4%)
Dec 2004
-$10.35M(-11.9%)
-$1.98M(-52.6%)
-$10.35M(-9.9%)
Sep 2004
-
-$4.17M(+131.4%)
-$11.49M(+14.3%)
Jun 2004
-
-$1.80M(-25.0%)
-$10.05M(-8.3%)
Mar 2004
-
-$2.40M(-23.0%)
-$10.96M(-6.6%)
Dec 2003
-$11.74M(-31.9%)
-$3.12M(+14.1%)
-$11.74M(+20.7%)
Sep 2003
-
-$2.73M(+0.6%)
-$9.73M(-20.3%)
Jun 2003
-
-$2.71M(-14.6%)
-$12.21M(-17.6%)
Mar 2003
-
-$3.18M(+188.2%)
-$14.81M(-14.0%)
Dec 2002
-$17.23M(-19.6%)
-$1.10M(-78.8%)
-$17.23M(-20.8%)
Sep 2002
-
-$5.21M(-2.0%)
-$21.74M(-4.4%)
Jun 2002
-
-$5.32M(-4.9%)
-$22.74M(+4.8%)
Mar 2002
-
-$5.59M(-0.4%)
-$21.69M(+1.2%)
Dec 2001
-$21.43M(+365.0%)
-$5.61M(-9.6%)
-$21.43M(+32.7%)
Sep 2001
-
-$6.21M(+45.4%)
-$16.15M(+29.2%)
Jun 2001
-
-$4.27M(-20.0%)
-$12.50M(+12.6%)
Mar 2001
-
-$5.34M(+1473.7%)
-$11.10M(+140.8%)
Dec 2000
-$4.61M(-50.1%)
-$339.10K(-86.7%)
-$4.61M(-17.7%)
Sep 2000
-
-$2.55M(-11.0%)
-$5.60M(+2.8%)
Jun 2000
-
-$2.87M(-349.2%)
-$5.45M(+5.2%)
Mar 2000
-
$1.15M(-186.7%)
-$5.18M(-43.9%)
Dec 1999
-$9.23M(+0.3%)
-$1.33M(-44.7%)
-$9.23M(+0.3%)
Sep 1999
-
-$2.40M(-7.7%)
-$9.20M(-13.2%)
Jun 1999
-
-$2.60M(-10.3%)
-$10.60M(+3.9%)
Mar 1999
-
-$2.90M(+123.1%)
-$10.20M(+10.9%)
Dec 1998
-$9.20M(+17.9%)
-$1.30M(-65.8%)
-$9.20M(-8.0%)
Sep 1998
-
-$3.80M(+72.7%)
-$10.00M(+22.0%)
Jun 1998
-
-$2.20M(+15.8%)
-$8.20M(+7.9%)
Mar 1998
-
-$1.90M(-9.5%)
-$7.60M(-2.6%)
Dec 1997
-$7.80M(-24.3%)
-$2.10M(+5.0%)
-$7.80M(-4.9%)
Sep 1997
-
-$2.00M(+25.0%)
-$8.20M(-2.4%)
Jun 1997
-
-$1.60M(-23.8%)
-$8.40M(-3.4%)
Mar 1997
-
-$2.10M(-16.0%)
-$8.70M(-15.5%)
Dec 1996
-$10.30M(+21.2%)
-$2.50M(+13.6%)
-$10.30M(+51.5%)
Sep 1996
-
-$2.20M(+15.8%)
-$6.80M(-20.9%)
Jun 1996
-
-$1.90M(-48.6%)
-$8.60M(-5.5%)
Mar 1996
-
-$3.70M(-470.0%)
-$9.10M(+7.1%)
Dec 1995
-$8.50M(-14.1%)
$1.00M(-125.0%)
-$8.50M(-30.3%)
Sep 1995
-
-$4.00M(+66.7%)
-$12.20M(+18.4%)
Jun 1995
-
-$2.40M(-22.6%)
-$10.30M(-4.6%)
Mar 1995
-
-$3.10M(+14.8%)
-$10.80M(+9.1%)
Dec 1994
-$9.90M(+65.0%)
-$2.70M(+28.6%)
-$9.90M(+20.7%)
Sep 1994
-
-$2.10M(-27.6%)
-$8.20M(+9.3%)
Jun 1994
-
-$2.90M(+31.8%)
-$7.50M(+17.2%)
Mar 1994
-
-$2.20M(+120.0%)
-$6.40M(+6.7%)
Dec 1993
-$6.00M(+36.4%)
-$1.00M(-28.6%)
-$6.00M(+20.0%)
Sep 1993
-
-$1.40M(-22.2%)
-$5.00M(-3.8%)
Jun 1993
-
-$1.80M(0.0%)
-$5.20M(+8.3%)
Mar 1993
-
-$1.80M(+12.5%)
-$4.80M(-5.9%)
Dec 1992
-$4.40M(-2.2%)
-
-
Oct 1992
-
-$1.60M(+14.3%)
-$5.10M(0.0%)
Jul 1992
-
-$1.40M(-6.7%)
-$5.10M(+13.3%)
Apr 1992
-
-$1.50M(+150.0%)
-$4.50M(+40.6%)
Apr 1992
-$4.50M(+32.4%)
-
-
Jan 1992
-
-$600.00K(-62.5%)
-$3.20M(-15.8%)
Oct 1991
-
-$1.60M(+100.0%)
-$3.80M(0.0%)
Jul 1991
-
-$800.00K(+300.0%)
-$3.80M(+11.8%)
Apr 1991
-$3.40M(+142.9%)
-$200.00K(-83.3%)
-$3.40M(+6.3%)
Jan 1991
-
-$1.20M(-25.0%)
-$3.20M(+60.0%)
Oct 1990
-
-$1.60M(+300.0%)
-$2.00M(+400.0%)
Jul 1990
-
-$400.00K
-$400.00K
Apr 1990
-$1.40M
-
-

FAQ

  • What is Celldex Therapeutics annual free cash flow?
  • What is the all time high annual FCF for Celldex Therapeutics?
  • What is Celldex Therapeutics annual FCF year-on-year change?
  • What is Celldex Therapeutics quarterly free cash flow?
  • What is the all time high quarterly FCF for Celldex Therapeutics?
  • What is Celldex Therapeutics quarterly FCF year-on-year change?
  • What is Celldex Therapeutics TTM free cash flow?
  • What is the all time high TTM FCF for Celldex Therapeutics?
  • What is Celldex Therapeutics TTM FCF year-on-year change?

What is Celldex Therapeutics annual free cash flow?

The current annual FCF of CLDX is -$159.70M

What is the all time high annual FCF for Celldex Therapeutics?

Celldex Therapeutics all-time high annual free cash flow is $16.98M

What is Celldex Therapeutics annual FCF year-on-year change?

Over the past year, CLDX annual free cash flow has changed by -$50.59M (-46.36%)

What is Celldex Therapeutics quarterly free cash flow?

The current quarterly FCF of CLDX is -$54.64M

What is the all time high quarterly FCF for Celldex Therapeutics?

Celldex Therapeutics all-time high quarterly free cash flow is $36.40M

What is Celldex Therapeutics quarterly FCF year-on-year change?

Over the past year, CLDX quarterly free cash flow has changed by -$13.65M (-33.32%)

What is Celldex Therapeutics TTM free cash flow?

The current TTM FCF of CLDX is -$173.35M

What is the all time high TTM FCF for Celldex Therapeutics?

Celldex Therapeutics all-time high TTM free cash flow is $34.79M

What is Celldex Therapeutics TTM FCF year-on-year change?

Over the past year, CLDX TTM free cash flow has changed by -$52.41M (-43.34%)
On this page